Releases - Artimplant

View:
 

Found press releases

 

Bulletin from Artimplant AB's Annual Meeting of Stockholders 2012

Adoption of financial statements, disposition of result and discharge of directors and officers
The financial statements of 2011 for the group and the parent company were adopted. The Annual Meeting decided that the Parent Company’s retained loss of SEK 9,235,880 will be carried forward and that no dividend will be paid. The directors and officers of the Company were granted discharge.

Election of Board members and...

ARTIMPLANT THREE - MONTH REPORT 2012


· Net revenue amounted to SEK 6.8 million (5.4), an increase of 27 percentage points.
· The net loss totaled SEK 2.3 million (3.9).  
· Earnings per stock unit amounted to SEK -0.01 (-0.03).
· The result has improved by SEK 1.6 million compared to the corresponding period last year.
· Positive sales trend on all markets. Own sales in the USA increased by 86 percentage points and in Europe by 42 percentage...

Changes of number of stock units and votes in Artimplant AB

With reference to Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (SFS 1991:980), it is hereby announced that the new issue of Series B stock units during March 2012 has led to the below changes in the number of stock units and votes in Artimplant AB.

Before the new issue: Series A stock units 575,000, Series B stock units 117.914.580, total number of stock units 118.489.580 and the number of...

Artimplant publishes the Annual Report of 2011

The Annual Report for the financial year 2011 is published through this press release and on the Company's homepage: http://www.artimplant.com/investors-media/annual-reports.html

For environmental and cost reasons a printed Annual Report will only be distributed to those who order a copy from the Company. A printed copy of the Annual Report can be...

Artimplant strenghtens its market position

Artimplant has entered into an agreement with its licensee, Biomet Sports Medicine, Inc., to assume total responsibility for sales of ATR products.
Biomet has held the license rights for our Artelon® Tissue Reinforcement (ATR) products since 2005. During 2007, the agreement was renegotiated from exclusive to non-exclusive for the US market. In conjunction with this, Artimplant began prospecting the market...

YEAR END REPORT JANUARY – DECEMBER 2011


· Net revenue amounted to SEK 18.3 million (18.5).*
· The net loss totaled SEK 17.9 million (22.4).  
· Earnings per stock unit amounted to SEK -0.15 (-0.32).
· Own sales as a proportion of total sales continued to increase and accounted for 75% (61) of product sales.
· The Company's cash flow objective is to achieve a positive cash flow before changes in working capital on a monthly basis during the fourth...

Artimplant takes over sales in the Nordic countries

Artimplant continues to strengthen its market position. Since the beginning of 2012, Artimplant has taken over the sales of their products on the Nordic market.
The former distributor, NMS, has filed for bankruptcy, enabling Artimplant to quickly take over the direct sales. This is a part of Artimplant's effort to increase its presence in markets where Artimplant's products are marketed and distributed.

Västra...

Artimplant invests in expanded own sales

With effect from January 1, 2012, Artimplant will take over responsibility for sales of Artelon® CMC Spacer, previously handled by the licensee SBi. This is an integral part of Artimplant's focus on reinforcing its presence on the very important US market.
Since December 2011, Artimplant has had a stronger sales organization in place in the USA, which it is felt will contribute positively to the company's...

Artimplant strengthens marketing organization in the USA

Jimmy Jones has been employed as President and Head of Marketing at the Artimplant subsidiary in the USA. Jones has more than 18 years' experience of the US orthopedics market and will bring considerable knowledge and expertise to Artimplant.
As part of the investment to reinforce the US organisation, two persons with long experience from the orthopedics market have been employed and at the same time three...

Election Committee 2012

It was decided at the Artimplant Annual General Meeting on May 4, 2011 that the Election Committee would comprise the Chairman of the Board of Directors plus three members appointed by the three largest stockholders, according to voting power, as of September 30, 2011.
The composition of the Election Committee must be announced no later than six months prior to the Annual General Meeting.

Up to the 2012 Annual...

Artimplant

Artimplant is a research- and development company, active within bio-materials.

View more


  CONTACT